NICE does not recommend Xtandi (enzalutamide) to treat prostate cancer- Astellas

The National Institute for Health and Care Excellence (NICE) has published draft guidelines rejecting the use of Xtandi (enzalutamide) from Astellas for advanced prostate cancer before chemotherapy. NICE recognised that the clinical trial results showed Xtandi can extend life when compared with placebo but it was not clear for how long. This was because there were �uncertainties associated with way the company had carried out adjustments to take account of the effect on length of life of treatments used when enzalutamide is no longer effective� The NICE appraisal committee was also concerned that Astellas �had not adequately evaluated the uncertainties in its cost-effectiveness analyses�.